NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/07/2024
Back to search
Official data from USPTO
SCANDION ONCOLOGY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SCANDION ONCOLOGY
ST13
US500000097313494Class
1, 5, 42
Filing
97313494
Registration
7376986
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
05/07/2024
Trademark type
Word
Nice classes
1, 5, 42
Filing date
03/15/2022
Registration date
05/07/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/07/2024
Last transaction
05/07/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
København Ø, DK
Examiner
SETTLES LEWIS, SHAILA E
Law office
M50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Scandion Oncology A/S
Representatives
Loren R. Hulse HOLLAND & HART LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Active chemical ingredients for use in the manufacture of anti-cancer drugs
Class 5
Anti-cancer preparations; Anti-cancer preparations of chemical origin; Anti-cancer preparations from hormones and antagonists; Anti-cancer preparations of microbial origin; Anti-cancer preparations of plant origin; Compounds for treating cancer; Pharmaceutical products for the treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Medical preparations for the treatment of cancer; Chemical preparations for medical purposes for the treatment of cancer; Biochemical preparations for medical use for the treatment of cancer; Biological preparations for medical purposes for the treatment of cancer; Anti-cancer drugs; Antitumor drugs; Injectable pharmaceuticals for the treatment of cancer; Medicinal preparations and substances for the treatment of cancer; Medicines for human purposes for the treatment of cancer; Medicines for the treatment of gastrointestinal diseases; Pharmaceutical compositions for the treatment of cancer; Pharmaceutical drugs for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for human use for the treatment of cancer; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceuticals for the treatment of cancer; Tumor suppressing agents; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Compounds for treating resistant cancers; Pharmaceutical preparations and substances for the treatment of treatment-resistant cancers
Class 42
Scientific research for medical purposes in the area of cancerous diseases; Medical research in the field of oncology
Publications
History of USPTO decisions and trademark events.
21 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/07/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/04/2024
PUBO
PUBLISHED FOR OPPOSITION
02/20/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/01/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
01/18/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/12/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/30/2023
ALIE
ASSIGNED TO LIE
11/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/26/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
03/24/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
03/24/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/26/2022
GNRT
NON-FINAL ACTION E-MAILED
12/26/2022
CNRT
NON-FINAL ACTION WRITTEN
12/26/2022
DOCK
ASSIGNED TO EXAMINER
12/26/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2022
NWAP
NEW APPLICATION ENTERED
03/18/2022
Continuous trademark protection
Get notified about every new filing that threatens SCANDION ONCOLOGY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.